Illumina's Proposed Acquisition of GRAIL Faces EU Jurisdiction Challenge
March 28, 2023
Biocom California said the European Court of Justice granted its application to intervene in support of Illumina’s challenge to the European Commission’s jurisdiction over Illumina’s proposed acquisition of GRAIL. Biocom California argued that the EU’s expanded merger-review approach—if upheld—could make it harder for small, growing life-science businesses to find investors.
- Buyers
- Illumina
- Targets
- GRAIL
- Industry
- Healthcare Services
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Radius Global Market Research Acquires Illuminas North America
January 7, 2025
Marketing & Advertising
Radius Global Market Research has acquired Illuminas North America, a multidisciplinary market research and data-science consultancy headquartered in Austin, Texas. The acquisition enhances Radius’s capabilities in technology-focused research, data science and customer insights to better serve its global B2B clients; financial terms were not disclosed.
-
Illumina Acquires Fluent BioSciences
July 9, 2024
Biotechnology
Illumina, Inc. has acquired Fluent BioSciences to integrate Fluent's PIPseq single-cell technology into Illumina's product portfolio and accelerate its multiomics capabilities. The acquisition, which closed July 9, 2024 and was funded with cash on hand, brings Fluent's accessible, scalable single-cell chemistry and the Fluent team into Illumina to expand end-to-end single-cell solutions for research and applied customers.
-
LuminUltra Acquires GL Biocontrol
September 16, 2025
Environmental Services
LuminUltra, a Canada-headquartered applied molecular diagnostics company backed by XPV Water Partners, has acquired France-based GL Biocontrol, a specialist in microbial testing and risk management for municipal and industrial water systems. GL Biocontrol will continue to operate under its name and will help LuminUltra establish France as its European headquarters while expanding its water diagnostics capabilities across Europe.
-
QIAGEN Acquires 96% Stake in BLIRT S.A.
May 11, 2022
Biotechnology
QIAGEN N.V. has acquired a more than 96% majority ownership stake in BLIRT S.A., a Gdansk, Poland–based manufacturer of recombinant enzymes and molecular biology reagents. The deal (expected to close in Q2 2022) adds R&D and industrial-scale manufacturing capacity, expands QIAGEN's sample technologies business and broadens its geographic and commercial reach while strengthening supply-chain resilience.
-
Eclipsebio Acquires Terrain Bio
January 29, 2026
Biotechnology
Eclipse Bioinnovations (Eclipsebio) has acquired Terrain Bio to integrate Terrain's AI/ML RNA design models and R&D-scale mRNA manufacturing analytics into Eclipsebio's sequencing-based validation platforms. The deal creates an end-to-end Design, Make, Test platform intended to accelerate RNA therapeutic development by connecting computational design directly to experimental feedback.
-
BioAgilytix Acquires Cambridge Biomedical
November 4, 2019
Healthcare Services
BioAgilytix, a GHO Capital portfolio company, has acquired Cambridge Biomedical, a Cambridge, Massachusetts–based clinical research organisation specializing in large-molecule bioanalysis. The deal expands BioAgilytix's laboratory capacity and capabilities (including CLIA/CAP/GLP capabilities and PCR/molecular suites), broadens its geographic footprint into the Boston/Cambridge biotech cluster, and strengthens its cell- and gene-therapy bioanalytical offerings.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.